ADR BioMedical Holdings has formulated a mid-term management plan for 2026-2028, aiming to expand sales from 750 million yen to 4.06 billion yen. The company plans to focus on new businesses and research & development to expand recurring revenue streams.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3750","jir_company_name":"ADR BioMedical Holdings Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/3750-20260721-01.pdf","jir_short_summary":"ADR BioMedical Holdings has formulated a mid-term management plan for 2026-2028, aiming to expand sales from 750 million yen to 4.06 billion yen. The company plans to focus on new businesses and research & development to expand recurring revenue streams.","jir_summary":"### Overview of the Mid-Term Management Plan\nADR BioMedical Holdings has formulated a mid-term management plan for 2026-2028 with the goal of expanding net sales from approximately 750 million yen to 4.06 billion yen. The company aims to expand recurring revenue streams through research & development and new business development. Special emphasis is placed on expanding its product portfolio with proprietary technologies and accumulating research data, as well as strengthening collaborations with medical and research institutions.\n\n### Future Outlook and Strategy\nThe company plans to promote research data accumulation and new product development, leveraging low-risk autograft procedures and emerging research-stage technologies. The expansion of recurring revenue streams aims to establish a stable earnings foundation and achieve long-term growth. Additionally, the company will strengthen direct sales to medical institutions and collaborations with academic organizations to promote the practical application and commercialization of research data.","jir_financial_highlights":"Net Sales: 750 million yen (Unknown)\nNet Sales: 4.06 billion yen (Approximately 5 times compared to FY2026 forecast)\nOperating Income: 30 million yen (Unknown)","jir_category":"","jir_hashtags":"#ADRBioMedicalHoldings, #MidTermManagementPlan, #JapanStocks","jir_key_figures":"Net Sales: 750 million yen (FY2026 forecast) \u2192 4.06 billion yen (FY2028 forecast)\nResearch data accumulation: approximately 3 times increase (comparison of horse implantation rates)\nNumber of research-stage data: over 500 cases","jir_meta_title":"\u3010ADR BioMedical\u3011 Formulation of Mid-Term Plan \uff5c FY2026-2028 Sales Expansion","jir_meta_description":"ADR BioMedical has formulated a mid-term management plan for FY2026-2028, focusing on sales growth and research data accumulation. Aiming to expand recurring revenue streams and strengthen business foundation.","jir_og_title":"ADR BioMedical's Mid-Term Plan \uff5c Sales Growth and Research Data Accumulation","jir_og_description":"ADR BioMedical has formulated a mid-term plan for FY2026-2028, promoting sales expansion and research data accumulation. Introducing strategies for steady growth.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":59367,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-86116","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n